PLACIDYL Drug Patent Profile

When do Placidyl patents expire, and when can generic versions of Placidyl launch?

Placidyl is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in PLACIDYL is ethchlorvynol. There is one drug master file entry for this compound. Additional details are available on the ethchlorvynol profile page.

Summary for PLACIDYL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	2,152
DailyMed Link:	PLACIDYL at DailyMed

US Patents and Regulatory Information for PLACIDYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	PLACIDYL	ethchlorvynol	CAPSULE;ORAL	010021-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbvie	PLACIDYL	ethchlorvynol	CAPSULE;ORAL	010021-010	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbvie	PLACIDYL	ethchlorvynol	CAPSULE;ORAL	010021-007	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbvie	PLACIDYL	ethchlorvynol	CAPSULE;ORAL	010021-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Placidyl (Ethchlorvynol) Market Dynamics, Financial Trajectory, and Exclusivity Analysis

Last updated: August 1, 2026

Placidyl, the brand name for ethchlorvynol, is a discontinued sedative-hypnotic that no longer has a meaningful commercial market in the United States. Abbott Laboratories marketed Placidyl primarily as an oral sleep medication before benzodiazepines and newer hypnotics displaced it. The product’s commercial decline reflected dependence liability, overdose risk, controlled-substance restrictions, generic substitution, and a shrinking clinical role. Abbott discontinued U.S. production in 1999, and no current FDA-approved Placidyl product supports branded revenue or generic launch activity in the U.S. market. [1][2]

What was Placidyl and how was ethchlorvynol used?

Placidyl was an oral sedative-hypnotic containing ethchlorvynol. It was prescribed for short-term treatment of insomnia. Historical labeling identified capsule strengths of 200 mg and 500 mg, with dosing adjusted according to patient response and clinical need. [1]

Ethchlorvynol is a non-barbiturate sedative with central nervous system depressant activity. Its therapeutic use declined as physicians shifted toward benzodiazepines, which offered more standardized dosing and broader clinical adoption, and later toward newer insomnia medicines with more targeted labeling.

Attribute	Placidyl / ethchlorvynol
Brand	Placidyl
Active ingredient	Ethchlorvynol
Therapeutic class	Sedative-hypnotic
Primary indication	Insomnia
Historical manufacturer	Abbott Laboratories
Dosage form	Oral capsules
U.S. regulatory status	Discontinued
Controlled-substance status	Schedule IV
Current U.S. commercial status	No active branded market
Main historical substitutes	Benzodiazepines, barbiturates, newer hypnotics

Ethchlorvynol’s pharmacologic profile created commercial disadvantages. Sedation, impaired coordination, respiratory-depression risk when combined with other depressants, and dependence potential limited long-term use. The product also had a narrow role after safer and more familiar alternatives became available.

When did Placidyl lose exclusivity and when was it discontinued?

Placidyl’s commercial exclusivity ended decades before its final U.S. withdrawal. The product was introduced in the 1950s, and the relevant patent and regulatory exclusivity periods expired long before Abbott stopped manufacturing it.

The important commercial dates are:

Period	Market event
1950s	Ethchlorvynol introduced as Placidyl
1960s-1970s	Broad use as a prescription sedative-hypnotic
1970s	Controlled-substance regulation increased distribution and prescribing controls
1980s-1990s	Benzodiazepines and newer hypnotics reduced demand
1999	Abbott discontinued U.S. manufacture of Placidyl
2000s onward	Product remained absent from the mainstream U.S. prescription market

The historical patent record does not create a current exclusivity barrier. No active U.S. product patent or regulatory exclusivity period is associated with marketed Placidyl today. The commercial question is therefore product abandonment, not patent expiration.

What was the FDA regulatory status of Placidyl?

Placidyl was an FDA-approved prescription drug, but it is no longer marketed in the United States. FDA’s discontinued-drug framework distinguishes commercial discontinuation from a formal safety withdrawal. Placidyl’s disappearance from the market reflects discontinuation of manufacturing and marketing rather than an active product protected by FDA exclusivity. [2]

Ethchlorvynol was placed in Schedule IV under the federal Controlled Substances Act. Schedule IV status imposed prescribing, dispensing, recordkeeping, and refill restrictions. The classification was less restrictive than Schedule II or Schedule III but still increased operational friction for prescribers, pharmacies, wholesalers, and manufacturers. [3]

The regulatory factors affecting Placidyl included:

• Controlled-substance inventory and recordkeeping requirements.
• Risk of misuse and dependence.
• Warnings regarding additive central nervous system depression.
• Limited suitability for chronic insomnia.
• Declining physician familiarity.
• Availability of substitute therapies with stronger commercial support.

What was the Orange Book status of Placidyl?

Placidyl has no active commercial Orange Book position supporting current market exclusivity. The product is not a current branded reference product with an enforceable patent listing that would block a modern Abbreviated New Drug Application.

For an active drug, Orange Book analysis would normally examine:

1. Listed patents covering the active ingredient, formulation, or method of use.
2. Pediatric exclusivity.
3. New chemical entity exclusivity.
4. Paragraph IV certifications by generic applicants.
5. Patent litigation under the Hatch-Waxman framework.

Those mechanisms are no longer commercially relevant to Placidyl. The product’s core chemical and historical formulation rights expired long ago, and no current U.S. generic filing campaign is publicly associated with ethchlorvynol.

How strong was the Placidyl patent estate?

The historical patent estate was weak by current pharmaceutical standards because it was built around an old small-molecule sedative with limited formulation complexity. Ethchlorvynol is not a biologic, complex injectable, long-acting delivery system, or specialized manufacturing platform. Its basic product architecture would have been comparatively straightforward to reproduce after expiration of the relevant rights.

Active-ingredient protection

Any patent protection covering ethchlorvynol itself would have expired many decades ago. The compound’s age eliminates the possibility of current composition-of-matter exclusivity in the United States.

Formulation protection

Historical Placidyl products used conventional oral dosage forms. Conventional capsule claims generally provide less durable protection than modern extended-release, multiparticulate, transdermal, inhaled, or depot formulations. No commercially significant modern formulation patent estate is associated with Placidyl.

Method-of-use protection

The product was used for insomnia, a broad indication that does not ordinarily support durable market protection once the underlying drug and formulation rights expire. No active method-of-use patent is publicly associated with Placidyl’s current U.S. market.

Manufacturing and process barriers

Ethchlorvynol does not present the manufacturing barriers associated with biologics, sterile injectables, viral vectors, antibody-drug conjugates, or highly potent oncology compounds. A theoretical reintroduction would face regulatory, quality, controlled-substance, and commercial barriers, but not a defensible patent moat.

Why did Placidyl lose market share?

Placidyl’s decline resulted from therapeutic substitution rather than a single competitive event.

Benzodiazepine displacement

Benzodiazepines became the dominant prescription sedative class for many indications during the period when Placidyl use was established. Drugs such as diazepam, temazepam, flurazepam, and later triazolam had stronger physician recognition and broader commercial distribution.

Newer insomnia products

Later non-benzodiazepine hypnotics, including zolpidem and related agents, entered a market that increasingly emphasized predictable pharmacology, short-term insomnia treatment, and branded promotional support. These drugs benefited from more contemporary clinical positioning than ethchlorvynol.

Safety and abuse concerns

Ethchlorvynol’s sedative effects and dependence potential reduced its attractiveness. Accidental overdose risk increased when combined with alcohol, opioids, barbiturates, or other central nervous system depressants. A product with a declining therapeutic role and controlled-substance obligations became difficult to justify commercially.

Physician and pharmacy behavior

As prescribing patterns changed, pharmacies had less incentive to maintain inventory of an infrequently used controlled substance. Reduced distribution lowered patient access and further weakened prescribing demand.

What was the financial trajectory of Placidyl?

Public filings do not generally disclose standalone Placidyl revenue, unit volume, gross margin, or product-level profitability. Abbott reported results at company and business-segment levels rather than providing a separate financial series for this legacy product. [4]

The financial trajectory can therefore be assessed directionally:

Financial phase	Commercial characteristics
Initial launch	New prescription sedative with limited direct competition
Expansion	Broad physician use and repeat prescription demand
Mature period	Established brand, but increasing generic and therapeutic substitution
Decline	Lower prescription volume, controlled-substance costs, reduced promotional value
Final phase	Manufacturing and distribution no longer economically justified
Post-1999	No material U.S. Placidyl revenue

Placidyl likely generated its highest commercial value during the period when prescription insomnia treatment relied heavily on older sedative agents and before benzodiazepines and newer hypnotics reshaped the category. The product’s mature-stage economics would have deteriorated as price competition, lower volume, and safety-management costs outweighed residual brand recognition.

The 1999 discontinuation indicates that Abbott viewed the product’s remaining commercial contribution as insufficient to support continued manufacturing and distribution. Discontinuation also removed costs associated with controlled-substance compliance, inventory management, pharmacovigilance, labeling, and supply-chain maintenance.

What companies challenged or replaced Placidyl?

No active Paragraph IV challenge program is associated with Placidyl today. The competitive pressure came from therapeutic substitutes and generic alternatives rather than from a recent litigation campaign.

Competitor category	Market effect
Benzodiazepines	Replaced older sedative-hypnotics in many prescribing settings
Barbiturates	Historically competed with Placidyl but later declined because of safety concerns
Zolpidem and related hypnotics	Offered newer insomnia positioning and stronger commercial adoption
Antidepressants used off-label	Expanded treatment alternatives for sleep complaints
Over-the-counter sleep aids	Captured lower-acuity and self-treatment demand
Behavioral insomnia treatment	Reduced reliance on chronic sedative prescribing in some settings

Generic competition mattered during Placidyl’s mature life, but the larger commercial force was substitution by other therapeutic classes. A generic version of an obsolete product does not preserve market value if physicians have moved to different treatments.

What patent litigation and settlement agreements affected Placidyl?

No material current patent litigation or settlement agreement affects Placidyl. The product predates the modern high-value Hatch-Waxman litigation model that now surrounds major branded drugs.

A current litigation search would not identify a meaningful Placidyl dispute involving:

• Paragraph IV invalidity or non-infringement claims.
• Orange Book patent listings.
• Authorized-generic agreements.
• First-filer settlements.
• Reverse-payment litigation.
• Biosimilar applications.
• Formulation patent enforcement.

Historical commercial disputes may have existed around manufacturing, distribution, or generic supply, but they do not create present market exposure.

Is there biosimilar or generic entry risk for Placidyl?

There is no biosimilar issue because ethchlorvynol is a synthetic small molecule, not a biologic. The relevant regulatory pathway would be an ANDA or, depending on the proposed product and historical reference-drug status, another abbreviated or full application pathway.

The practical generic-entry risk is negligible because the U.S. branded product has already left the market. A hypothetical reintroduction would face a different set of risks:

• Limited physician demand.
• Established preference for newer insomnia medicines.
• Controlled-substance compliance requirements.
• Potential safety scrutiny.
• Low expected prescription volume.
• Retail pharmacy reluctance to stock the product.
• Difficulty securing commercial reimbursement.
• Limited payer incentive to cover an obsolete sedative.

The absence of a patent barrier would make technical entry easier, but it would not make commercial entry attractive.

What generic launch scenarios exist for ethchlorvynol?

Three scenarios can be distinguished.

No-launch scenario

This is the most commercially rational outcome. A manufacturer would avoid development because the addressable market is small, the product has weak clinical differentiation, and regulatory and controlled-substance costs would consume a disproportionate share of expected revenue.

Niche reintroduction

A specialty manufacturer could theoretically pursue ethchlorvynol for a narrow patient population or a specific institutional-use segment. Such a strategy would require evidence that clinicians need an alternative unavailable from current hypnotics. No established market signal supports this scenario.

Low-price generic supply

A manufacturer could seek approval as a low-cost generic and rely on limited institutional or prescriber demand. The low unit price and small volume would make the product vulnerable to supply interruptions and manufacturer exit.

How does Placidyl compare with modern insomnia drugs?

Placidyl is commercially disadvantaged against current insomnia therapies on clinical familiarity, regulatory positioning, supply availability, and payer acceptance.

Factor	Placidyl	Modern insomnia therapies
Market status	Discontinued	Active markets
Clinical familiarity	Low	High for leading agents
Patent position	Expired or irrelevant	Varies by product
Formulation innovation	Limited	Includes modified-release and targeted products
Controlled-substance exposure	Yes	Varies
Promotional support	None	Present for selected branded products
Pharmacy availability	Absent or limited	Broad for established products
Reimbursement	No meaningful current coverage	Established payer pathways for active products
Commercial growth	None	Product-specific growth or decline

Placidyl’s historical brand recognition does not translate into current pricing power. In pharmaceutical markets, an old brand can retain value only if it has continuing clinical demand, supply availability, regulatory relevance, or a differentiated formulation. Placidyl has none of those commercial supports.

What geographic markets still matter for Placidyl?

The United States is the principal market for assessing Placidyl’s commercial history because Abbott’s product and discontinuation are most clearly documented there. No meaningful current global market is established for Placidyl as a branded product.

Any residual ethchlorvynol availability outside the United States would need to be assessed jurisdiction by jurisdiction through national product registries, controlled-substance rules, and local marketing authorization databases. It should not be treated as evidence of a viable global franchise. The product has no current multinational commercial platform comparable to active hypnotic brands.

What would a reintroduction require?

A modern sponsor seeking to revive ethchlorvynol would need to address regulatory, clinical, manufacturing, and commercial requirements:

• Establish a legally viable FDA application pathway.
• Demonstrate quality, safety, and efficacy under current standards.
• Produce validated active pharmaceutical ingredient and finished-dose manufacturing.
• Comply with controlled-substance registration and security requirements.
• Update labeling and risk-management materials.
• Establish a pharmacovigilance system.
• Build a distribution network willing to handle the product.
• Obtain payer and pharmacy access.
• Demonstrate clinical or economic differentiation from current alternatives.

Patent ownership would not be the principal obstacle. The primary barriers would be clinical relevance, regulatory risk, demand generation, controlled-substance operations, and return on investment.

Key Takeaways

• Placidyl is the discontinued Abbott brand for ethchlorvynol, an older sedative-hypnotic used for insomnia.
• Abbott discontinued U.S. manufacture in 1999.
• No active U.S. patent or regulatory exclusivity currently supports Placidyl.
• Placidyl has no meaningful current Orange Book, Paragraph IV, biosimilar, or patent-litigation exposure.
• The product’s decline resulted from therapeutic substitution, safety concerns, controlled-substance restrictions, and weak commercial economics.
• Abbott did not publicly report standalone Placidyl revenue, so the financial trajectory must be assessed through product lifecycle and discontinuation evidence rather than audited product-level sales.
• A generic or branded reintroduction would face low demand and high commercial risk despite the absence of an effective patent barrier.
• The relevant competitive set is modern insomnia therapy, not legacy sedative brands.

FAQs About Placidyl and Ethchlorvynol

Is Placidyl still available by prescription?

No current U.S. branded Placidyl product is marketed. Abbott discontinued U.S. production in 1999.

What drug replaced Placidyl?

No single product replaced it. Benzodiazepines, zolpidem-class hypnotics, newer insomnia therapies, over-the-counter products, and behavioral treatment absorbed different portions of its former use.

Does Placidyl have an active patent?

No commercially relevant active U.S. patent estate is associated with Placidyl. Any original compound or product patents expired many decades ago.

Was Placidyl a controlled substance?

Yes. Ethchlorvynol was classified as a Schedule IV controlled substance in the United States.

Could a company relaunch ethchlorvynol?

A relaunch could be legally possible through an appropriate FDA pathway, but the product would face weak demand, safety concerns, controlled-substance compliance costs, and competition from established insomnia treatments.

References

1. Abbott Laboratories. (1999). Placidyl (ethchlorvynol) prescribing information. Abbott Laboratories.

2. U.S. Food and Drug Administration. (n.d.). FDA Drug Safety and availability: Discontinued drugs and drug products. https://www.fda.gov/

3. U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules. https://www.dea.gov/drug-information/drug-scheduling

4. Abbott Laboratories. (1999). Annual report. Abbott Laboratories.